Zürich Switzerland 17th of April 2019 – HypoPet AG today announced the publication of important preclinical data for their cat allergy vaccine, HypoCat™. The data were published online 17th of April 2019 in an article entitled “Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. “in the Journal of Allergy and Clinical Immunology.
The published work, led by HypoPet’s Zurich-based research team (in collaboration with researchers from the Latvian Biomedical Research and Study Centre Riga, Vetsuisse Faculty University of Zurich and the Functional Genomics Centre Zürich, University of Zürich), showed that HypoPet’s virus-like particle vaccine targeting the major feline allergen (i.e. Fel d 1) to which humans are allergic, successfully induced Fel d 1 binding antibodies in cats and that these antibodies neutralized the allergen. Furthermore, the HypoCat™ vaccine was reported to be well tolerated without any overt toxicity. The data described in the paper were generated from 4 separate studies involving a total of 54 cats.
Dr Gary Jennings, CEO of HypoPet AG, commented, “We are very pleased to publish this data which shows our HypoCat™ vaccine is able to produce high levels of antibodies in cats and that these antibodies can bind and neutralize the Fel d 1 allergen produced by the animals. This work was a key step in the milestone driven development of HypoCat™, the lead project in our product pipeline. Moreover, our development partner Benchmark Holdings recently announced successful completion of other key safety and efficacy trials and transfer of the HypoCat manufacture process to GMP. Consequently, we are pressing ahead with registration studies and discussions with European and U.S regulators with the hope of bringing this much-needed product to the market”